Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.43 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | VDR | P11473 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928969 | 1.00 | SLC16A3 (0.43) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL1929942 | 0.92 | ALDH1A1 (0.38) | PPARDPPARGPPARAVDRALDH1A1 | |
| SCHEMBL1929945 | 0.92 | ALDH1A1 (0.38) | PPARDPPARGPPARAVDRALDH1A1 | |
| SCHEMBL3974627 | 0.91 | ALDH1A1 (0.47) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL3971072 | 0.91 | ALDH1A1 (0.47) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL14281456 | 0.91 | ALDH1A1 (0.47) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL4487604 | 0.91 | SLC16A3 (0.44) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL4386902 | 0.91 | SLC16A3 (0.44) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL4386900 | 0.91 | SLC16A3 (0.44) | SLC16A3SLC16A1PPARDPPARGPPARA | |
| SCHEMBL1927836 | 0.91 | PPARD (0.40) | SLC16A3SLC16A1PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956077-B2 | 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| EP-1778655-B1 | 2 - { - 3 2 - (PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDS (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20070197613-A1 | 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197613-A1 | 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, PPARD | SLC16A3 1062/4885SLC16A1 1224/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.